Market Cap
$2.5B
CLDX
Celldex Therapeutics, Inc.
$32.28 ▲ +0.31%
Prev close $32.18Market cap$2.5B
ConsensusStrong Buy
12-mo target$63.07 (+95.4%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)32 New Institutional Positions11 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CLDX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (91%)
Inst. Holders
50 funds
Inst. Value
$1.9B
Inst. Activity
32 buys / 11 sells
Social Sentiment
60° Warm
SEC Reports
6
Press Releases
7
Price chart 30d -18.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: CLDX — 61.6% short (0.4M / 0.6M)
Short: 389,872 | Exempt: 752 | TRF Vol: 632,465 | Short Ratio: 61.6% | Off-exchange volume (dark poo
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
7,002,530 shares ($260.6M)
Jun 30, 2026 Inst.
STATE STREET CORP — ADD
3,900,427 shares ($145.1M)
Jun 25, 2026 Insider
PENNER HARRY JR was granted 26,000 shares
Director
Jun 25, 2026 Insider
NEIL GARRY ARTHUR was granted 26,000 shares
Director
Jun 25, 2026 Insider
Jun 14, 2026 SEC Cohen Cheryl was granted 26,000 shares
Director
Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by 10.8%. The press release focuses on positive long
PRESS-RELEASE — Impact 6/10
Celldex presented positive Phase 1 data for CDX-622, a bispecific antibody targeting SCF and TSLP, at EAACI. The drug sh
Impact 7/10
Analyst ratings buy % +11.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
91% rate it Buy or better · 22 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Sep 23, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
| Sep 23, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Sep 22, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Sep 22, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
| Sep 10, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Aug 7, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Aug 7, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Jul 29, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Jul 22, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Aug 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Jul 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Jun 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Apr 1, 2026 | 7 | 12 | 2 | 1 | 0 | 86% | |
| Mar 1, 2026 | 6 | 12 | 3 | 1 | 0 | 82% | |
| Feb 1, 2026 | 6 | 12 | 3 | 1 | 0 | 82% |
Price targets
Where 14 covering analysts think CLDX trades over the next 12 months.
$63.07 +95.4% upside Strong Buy
Current$32.28 Low$28.00 Median$64.00 High$100.00 14 analysts
$28.00$100.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
60°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 1 bullish, 1 bearish, 2 mixed, 2 neutral · avg impact 5.7/10.Plus 7 press releases.
BEARISHPRESS-RELEASE6/10
Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by 10.8%. The press release focu
Jun 14, 2026
NEUTRALINST-CLUSTER4/10
A mixed institutional cluster in CLDX for Q3 2025 shows two mega-passive buyers (Wells Fargo, Invesc
Jun 11, 2026
MIXED8-K6/10
Celldex reported Q1 2026 results with a net loss of $78.7M (-$1.18/share), wider than the $53.8M los
May 7, 2026
MIXEDPRESS-RELEASE6/10
Celldex reported Q1 2026 EPS of -$1.18 (miss vs -$1.13 consensus) and revenue of $15K (miss vs $861K
May 7, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: CLDX — 61.6% short (0.4M / 0.6M)
Short: 389,872 | Exempt: 752 | TRF Vol: 632,465 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: CLDX — 64.3% short (0.3M / 0.5M)
Short: 344,562 | Exempt: 60 | TRF Vol: 535,787 | Short Ratio: 64.3% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: CLDX — 64.2% short (0.5M / 0.7M)
Short: 455,147 | Exempt: 0 | TRF Vol: 708,690 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: CLDX — 67.0% short (0.6M / 0.9M)
Short: 600,990 | Exempt: 0 | TRF Vol: 896,848 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: CLDX — 67.0% short (0.6M / 0.9M)
Short: 605,181 | Exempt: 0 | TRF Vol: 903,922 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.01 | $-1.07–$-0.94 | -0.1% | -0.5% | 5↑ 1↓ | $0.0B | 10 |
| Next Q | $-1.01 | $-1.12–$-0.87 | 17.2% | -1.1% | 5↑ 1↓ | $0.0B | 10 |
| Current FY | $-4.12 | $-4.33–$-3.71 | -5.7% | -0.4% | 6↑ 0↓ | $0.0B | 10 |
| Next FY | $-4.24 | $-5.00–$-3.26 | -2.7% | -1.8% | 6↑ 2↓ | $0.0B | 10 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.011 | — |
| 7d ago | $-1.011 | — |
| 30d ago | $-1.005 | -0.006 |
| 60d ago | $-1.081 | +0.070 |
| 90d ago | $-1.081 | +0.070 |
Institutional ownership
Which big funds own CLDX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.9B total value (50,139,261 shares) as of 2026-Q2. Top holders: NOMURA, WELLINGTON, BlackRock,. Net buying activity: 32 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 9,543,671 | $355.1M | 19.0% | — |
| BlackRock, Inc. | 7,002,530 | $260.6M | 14.0% | ADD +30.4% |
| STATE STREET CORP | 3,900,427 | $145.1M | 7.8% | ADD +39.1% |
| FMR LLC | 3,722,888 | $138.5M | 7.4% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,464,831 | $128.9M | 6.9% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,022,226 | $75.3M | 4.0% | — |
| GOLDMAN SACHS GROUP INC | 1,615,343 | $60.1M | 3.2% | ADD +63.4% |
| BAKER BROS. ADVISORS LP | 1,182,611 | $44.0M | 2.4% | ADD +77.7% |
| MILLENNIUM MANAGEMENT LLC | 1,170,787 | $43.6M | 2.3% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 5,369,885 | 7,002,530 | +30.4% | $260.6M |
| STATE STREET CORP | ADD | 2,804,168 | 3,900,427 | +39.1% | $145.1M |
| GOLDMAN SACHS GROUP INC | ADD | 988,416 | 1,615,343 | +63.4% | $60.1M |
| BAKER BROS. ADVISORS LP | ADD | 665,370 | 1,182,611 | +77.7% | $44.0M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | NEW | — | 989,442 | — | $36.8M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 629,252 | 863,536 | +37.2% | $32.1M |
| Assenagon Asset Management S.A. | DOUBLED | 146,525 | 788,696 | +438.3% | $29.3M |
| Woodline Partners LP | ADD | 500,127 | 700,830 | +40.1% | $26.1M |
| PANAGORA ASSET MANAGEMENT INC | DOUBLED | 142,327 | 572,538 | +302.3% | $21.3M |
| Nuveen, LLC | DOUBLED | 201,949 | 568,460 | +181.5% | $21.2M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
18 insiders, 18 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 25, 2026 | PENNER HARRY JR | Director | AWARD | 26,000 | — | — |
| Jun 25, 2026 | NEIL GARRY ARTHUR | Director | AWARD | 26,000 | — | — |
| Jun 25, 2026 | Cohen Cheryl | Director | AWARD | 26,000 | — | — |
| Jun 25, 2026 | Torres Denice | Director | AWARD | 26,000 | — | — |
| Jun 25, 2026 | Brownlie Keith L | Director | AWARD | 26,000 | — | — |
| Jun 25, 2026 | MARINO JAMES J | Director | AWARD | 26,000 | — | — |
| Jun 25, 2026 | Jain Rita | Director | AWARD | 26,000 | — | — |
| Jun 25, 2026 | Marucci Anthony S | PRESIDENT & CEO | AWARD | 375,000 | — | — |
| Jun 25, 2026 | Crowley Elizabeth | SR. VP & CPDO | AWARD | 100,000 | — | — |
| Jun 25, 2026 | PEPIN RONALD | SR. VP & CBO | AWARD | 20,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CLDX.
Shares short
8,953,127
Settlement Sep 15, 2026
Change vs prior
+3.6%
Semi-monthly cycle
Days to cover
13.1
At avg daily volume
Of shares outstanding
≈11.4%
Estimate — not % of float
All CLDX filing & press-release reports (13)
- PRESS-RELEASE reportJun 14, 2026
- PRESS-RELEASE reportJun 14, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportJun 10, 2026
- 8-K reportMay 7, 2026
- PRESS-RELEASE reportMay 7, 2026
- PRESS-RELEASE reportApr 6, 2026
- PRESS-RELEASE reportApr 2, 2026
- 424B5 reportApr 1, 2026
- PRESS-RELEASE reportApr 1, 2026
- PRESS-RELEASE reportMar 27, 2026
- PRESS-RELEASE reportMar 1, 2026
- INST-CLUSTER reportFeb 28, 2026